posted on 2024-11-07, 13:58authored byClare Puttick, Thomas P Jones, Michelle M Leung, Felipe Galvez-Cancino, Jiali Liu, Manuel Varas-Godoy, Andrew Rowan, Oriol Pich, Carlos Martinez-Ruiz, Robert Bentham, Krijn K Dijkstra, James RM Black, Rachel Rosenthal, Nnennaya Kanu, Kevin Litchfield, Roberto Salgado, David A Moore, Peter Van Loo, Mariam Jamal-Hanjani, Sergio A Quezada, TRACERx Consortium, Charles Swanton, Nicholas McGranahan
Disruption of the class I human leukocyte antigen (HLA) molecules has important implications for immune evasion and tumor evolution. We developed major histocompatibility complex loss of heterozygosity (LOH), allele-specific mutation and measurement of expression and repression (MHC Hammer). We identified extensive variability in HLA allelic expression and pervasive HLA alternative splicing in normal lung and breast tissue. In lung TRACERx and lung and breast TCGA cohorts, 61% of lung adenocarcinoma (LUAD), 76% of lung squamous cell carcinoma (LUSC) and 35% of estrogen receptor-positive (ER+) cancers harbored class I HLA transcriptional repression, while HLA tumor-enriched alternative splicing occurred in 31%, 11% and 15% of LUAD, LUSC and ER+ cancers. Consistent with the importance of HLA dysfunction in tumor evolution, in LUADs, HLA LOH was associated with metastasis and LUAD primary tumor regions seeding a metastasis had a lower effective neoantigen burden than non-seeding regions. These data highlight the extent and importance of HLA transcriptomic disruption, including repression and alternative splicing in cancer evolution.
Funding
Crick (Grant ID: CC2088, Grant title: Kassiotis CC2088)
Crick (Grant ID: CC2008, Grant title: Van Loo CC2008)
Crick (Grant ID: CC2041, Grant title: Swanton CC2041)
Crick (Grant ID: CC1119, Grant title: STP Scientific Computing)
Crick (Grant ID: CC1062, Grant title: STP Flow Cytometry)
Crick (Grant ID: CC1061, Grant title: STP Experimental Histopathology)
Crick (Grant ID: CC1107, Grant title: STP Bioinformatics & Biostatistics)
Crick (Grant ID: CC1064, Grant title: STP Advanced Sequencing)
Novo Nordisk UK Research Foundation (Grant ID: NNF15OC0016584, Grant title: NovoNordisk Foundation 16584)
European Research Council (Grant ID: 835297 - PROTEUS, Grant title: ERC 835297 - PROTEUS)